As the Nasdaq reaches record highs driven by surges in chip stocks and Apple, while the S&P 500 shows signs of losing momentum, investors are keenly observing market fluctuations influenced by tariff ...

Palleon Pharmaceuticals has dosed the first subject in the randomised Phase II trial of E-602 (HLX79), a first-in-class human ...

ABCL-575’s predicted dosing schedule of every six months is enabled by a "human half-life of approximately 67 days," as ...